M&AThalia buys Sanmirna, becomes a clinical-stage RNA companyThalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten … more ➔
Start-upMerck launches build-to-buy Saturnus Bio with $50mMerck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies. more ➔
Start-upTRIMTECH extends seed round to $47M for protein degradation drugsUK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million. more ➔
Market accessAfter FDA rejection, Sanofi’s BTK inhibitor wins EU approvalSanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous … more ➔
M&ACan Sanofi buy its way into in vivo CAR-T?Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from … more ➔
Start-upBionyra launches with $165m, France’s largest biotech Series AWith an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year … more ➔
licensingBioArctic signs potential $1bn Alzheimers research deal with Eli LillyBioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with … more ➔
investmentNovo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discoveryThe Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation … more ➔
licensingJazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCelleraDublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and … more ➔
clinical dataF2G’s oral antifungal clears Phase III hurdleUK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening … more ➔
